Skyclarys

(Omaveloxolone)

Skyclarys

Drug updated on 11/17/2023

Dosage FormCapsule (oral: 50 mg)
Drug ClassNuclear factor (erythroid-derived 2)-like 2 (Nrf2) activator
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

Product Monograph / Prescribing Information

Document TitleYearSource
Skyclarys (omaveloxolone) Prescribing Information. 2023Reata Pharmaceuticals, Inc., Plano, TX

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review. 2022Therapeutic Advances in Rare Disease